Nanobiotix shares rose in trading after a report said Johnson & Johnson is studying a possible takeover of the French biotechnology firm. The market reaction reflected renewed attention on the company’s partnership with the healthcare giant on a cancer therapy.
The report, published by La Lettre, prompted an initial jump in Nanobiotix stock of as much as 15% before gains were pared; later in the session the shares remained higher by about 4%. Overall session moves included a peak increase reported at 12% following the takeover speculation.
Requests for immediate comment went unanswered by representatives for both Johnson & Johnson and Nanobiotix, according to accounts of the situation.
Analysts at Van Lanschot Kempen weighed in after the report. Chiara Montironi, who covers the name with a buy rating, relayed that Nanobiotix’s management told the firm a journalist from La Lettre reached out after takeover rumors circulated within the investor community. In that communication the company indicated it had "no indication of interest from J&J for a potential takeover," the analyst wrote.
Van Lanschot Kempen also argued that a transaction appears unlikely at this point because, under the existing partnership, Johnson & Johnson holds the exclusive license to NBTXR3. The bank noted that arrangement gives J&J "the full strategic and the majority of the financial ownership," reducing incentives or practical pathways for an outright takeout at present. In the analysts’ words, a "takeout at this stage is unlikely."
Reports from other outlets also reflected similar lines from Nanobiotix. According to Bloomberg, the company is not aware of Johnson & Johnson studying a move to take control of the business.
The episode underscores how takeover chatter, even when not confirmed, can quickly move share prices—particularly when the companies involved already have close development ties. In this instance, the market reaction was immediate and volatile, with intraday swings between the initial surge and more modest net gains by the session’s close.
Key contextual details contained in public statements:
- La Lettre reported that J&J is examining a takeover of Nanobiotix.
- Nanobiotix is partnered with Johnson & Johnson on the development of a cancer drug.
- Van Lanschot Kempen stated a takeout at this stage is unlikely because J&J holds the exclusive license to NBTXR3.